{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-25-000089","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.271898+00:00","generated_at":"2026-05-17T02:35:13.643100+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Ozekibart meets primary endpoint in chondrosarcoma; BLA submission planned Q2 2026","bullets":["ChonDRAgon study achieved primary endpoint: 52% reduction in risk of progression or death (HR=0.479; p<0.0001); median PFS 5.52 vs 2.66 months.","Disease control rate 54% (ozekibart) vs 27.5% (placebo); benefit consistent across IDH subgroups.","CRC expansion cohort (n=26 evaluable): 23% ORR, 92% disease control rate in heavily pretreated patients.","Ewing sarcoma expansion (n=25 evaluable): 64% ORR, 92% disease control rate; typical standard of care ORR 15-30%.","One fatal hepatotoxicity event early in study; risk mitigated by excluding severe liver impairment and close monitoring; overall hepatic AEs 11.8% vs 4.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-25-000089","json":"https://secwatch.observer/filing/0002007919-25-000089.json","markdown":"https://secwatch.observer/filing/0002007919-25-000089.md","text":"https://secwatch.observer/filing/0002007919-25-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000089/0002007919-25-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000089/inhibrx-20251023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:35:13.643100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}